Abstract P5-19-12: Subgroup analysis on efficacy in the routine treatment - Results of the 2nd inter… - SLUB Dresden

Medientyp: E-Artikel
Titel: Abstract P5-19-12: Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR+ Women"
Beteiligte: Jackisch, Christian; Grischke, Eva-Maria; Schneeweiss, Andreas; Decker, Thomas; Uleer, Christoph; Förster, Frank; Tomé, Oliver; Wimberger, Pauline; Kurbacher, Christian M; Mueller, Bettina; Harbeck, Nadia; Mundhenke, Christoph; Kuemmel, Sherko; Muth, Mathias; Kreuzeder, Julia; Bloch, Wilhelm; Tesch, Hans; Lüftner, Diana; Schütz, Florian; Fasching, Peter A
Erschienen: American Association for Cancer Research (AACR), 2015
Erschienen in: Cancer Research
Sprache: Englisch
DOI: 10.1158/1538-7445.sabcs14-p5-19-12
ISSN: 0008-5472; 1538-7445
Schlagwörter: Cancer Research ; Oncology
Entstehung:
Anmerkungen:
Beschreibung: <jats:title>Abstract</jats:title> <jats:p>Introduction</jats:p> <jats:p>BRAWO is a German non-interventional study of 3000 patients (pts) with advanced or metastatic, hormone-receptor-positive, HER2-negative breast cancer treated with everolimus (EVE) and exemestane (EXE). We report results of the 2nd preplanned interim analysis (IA) with a data cut-off on 8th July 2014.</jats:p> <jats:p>Methods</jats:p> <jats:p>BRAWO collects data on the routine clinical treatment with EVE and EXE at about 400 sites. Main objectives are to extend the knowledge on a) the efficacy in the clinical routine and the impact of physical activity on efficacy and quality of life, b) prophylaxis and management of stomatitis, and c) the sequence of therapy in the clinical routine. The 2nd IA was defined to take place 12 months after the inclusion of the 500. patient into the documentation.</jats:p> <jats:p>Results</jats:p> <jats:p>Efficacy data will be reported for the first 500 documented pts. Apart from data on the total study population we will present the PFS results for subgroups including pts with or without prior EXE therapy, with or without prior chemotherapy for the advanced setting, with or without visceral metastasis and with regard to the line of treatment in the advanced setting and the extent of physical activity. The respective summary of adverse events for these patients will be presented as well as results on treatment compliance and dosing. Baseline characteristics and medical history as well as insights into treatment sequences before EVE and EXE will further be shown for all enrolled patients with valid baseline documentation (approx. 1200).</jats:p> <jats:p>Conclusion</jats:p> <jats:p>This subgroup analysis will provide insights into the treatment efficacy in the clinical routine and will add to a more comprehensive understanding of the treatment with EVE/EXE.</jats:p> <jats:p>Citation Format: Christian Jackisch, Eva-Maria Grischke, Andreas Schneeweiss, Thomas Decker, Christoph Uleer, Frank Förster, Oliver Tomé, Pauline Wimberger, Christian M Kurbacher, Bettina Mueller, Nadia Harbeck, Christoph Mundhenke, Sherko Kuemmel, Mathias Muth, Julia Kreuzeder, Wilhelm Bloch, Hans Tesch, Diana Lüftner, Florian Schütz, Peter A Fasching. Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR+ Women" [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P5-19-12.</jats:p>
Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: